Head & Neck Cancer Clinical Trials

22 recruitingLast updated: June 17, 2026

There are 22 actively recruiting head & neck cancer clinical trials across 10 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Shanghai, China, Charlottesville, Virginia, United States, Chengdu, China, China. Updated daily from ClinicalTrials.gov.


Head & Neck Cancer Trials at a Glance

22 actively recruiting trials for head & neck cancer are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Shanghai, Charlottesville, and Chengdu. Lead sponsors running head & neck cancer studies include Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Centre Henri Becquerel, and Banaras Hindu University.

Browse head & neck cancer trials by phase

Treatments under study

About Head & Neck Cancer Clinical Trials

Looking for clinical trials for Head & Neck Cancer? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Head & Neck Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Head & Neck Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 1

Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors

Head & Neck CancerNasopharyngeal Cancinoma (NPC)
West China Hospital9 enrolled1 locationNCT07625423
Recruiting

REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors

Head & Neck Cancer
Istituto Clinico Humanitas50 enrolled1 locationNCT07635641
Recruiting
Not Applicable

Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery

Head & Neck Cancer
Tianjin Medical University Cancer Institute and Hospital80 enrolled1 locationNCT07622381
Recruiting
Phase 2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyHead and Neck Squamous Cell Carcinoma+1 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine182 enrolled1 locationNCT07601737
Recruiting
Phase 3

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Head & Neck CancerPostoperative Adjuvant TreatmentHead & Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University370 enrolled1 locationNCT07445048
Recruiting

Role of the Immune System in Preventing Laryngeal Cancer

Head & Neck Cancer
European Institute of Oncology3 enrolled1 locationNCT07508319
Recruiting

FL-261 Imaging for Cancer Diagnosis and Staging

Colorectal, CancerNon-small Cell Lung CancerAdvanced Solid Tumors+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07510321
Recruiting
Phase 2

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Head & Neck CancerMetastatic Squamous Cell CarcinomaOropharynx Squamous Cell Carcinoma+3 more
Wake Forest University Health Sciences32 enrolled1 locationNCT04858269
Recruiting

Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

Head & Neck CancerHead & Neck Squamous Cell Carcinoma
University of Rome Tor Vergata25 enrolled1 locationNCT07448727
Recruiting
Not Applicable

Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

Squamous Cell Cancer of Head and Neck (SCCHN)Head & Neck CancerCancer Pain
University of Virginia20 enrolled6 locationsNCT07405645
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Phase 1

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Head and Neck CancerSolid TumorsHNSCC+10 more
VLP Therapeutics41 enrolled1 locationNCT06736379
Recruiting
Not Applicable

Improving Dental Care for Patients With Head and Neck Tumors

Head & Neck CancerOral Health CareOral Health Behavior Change+2 more
University Medical Center Goettingen132 enrolled1 locationNCT07328347
Recruiting
Phase 2

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Head & Neck Cancer
Tang-Du Hospital10 enrolled1 locationNCT07353723
Recruiting
Phase 3

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Head & Neck CancerHead & Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute335 enrolled1 locationNCT07333274
Recruiting
Phase 2Phase 3

Contrast-enhanced Ultrasound for Sentinel Node Detection

Breast CancerMelanomaHead & Neck Cancer
The Netherlands Cancer Institute91 enrolled1 locationNCT07310758
Recruiting
Not Applicable

Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer

Head & Neck Cancer
Centre Henri Becquerel10 enrolled1 locationNCT07285564
Recruiting
Phase 1Phase 2

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Head & Neck CancerIntratumoral Injection
Coordination Pharmaceuticals, Inc.16 enrolled1 locationNCT05838729
Recruiting

Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas

Head & Neck CancerOropharyngeal Neoplasms
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh550 enrolled1 locationNCT06642324
Recruiting

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Breast CancerGastric CancerLung Cancer+5 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS420 enrolled1 locationNCT05878964